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There is increasing awareness of reactions to vaccination 
that include persistent skin reactions. We present here a 
retrospective investigation of long-lasting skin reactions 
and aluminium hypersensitivity in children, based on 
medical records and questionnaires sent to the parents. 
In the 10-year period 2003 to 2013 we identified 47 child-
ren with persistent skin reactions caused by childhood 
vaccinations. Most patients had a typical presentation of 
persisting pruritic subcutaneous nodules. Five children 
had a complex diagnostic process involving paediatri-
cians, orthopaedics and plastic surgeons. Two patients 
had skin biopsies performed from their skin lesions, and 
2 patients had the nodules surgically removed. Forty-
two children had a patch-test performed with 2% alumi-
nium chloride hexahydrate in petrolatum and 39 of them 
(92%) had a positive reaction. The persistent skin reac-
tions were treated with potent topical corticosteroids and 
disappeared slowly. Although we advised families to con-
tinue vaccination of their children, one-third of parents 
omitted or postponed further vaccinations. Key words: 
persistent skin reactions; aluminium hypersensitivity; pru-
ritic nodule; contact allergy; childhood vaccinations.
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Aluminium is a ubiquitous metal, which is used for 
many different purposes, e.g. in cooking utensils, buil-
ding materials, consumer products, antiperspirants and 
other cosmetics (1). Aluminium is used as an adjuvant 
in vaccines and allergen immunotherapy, to enhance a 
specific and longer-lasting immune response, although 
the exact mechanism remains a target of research (2). 
Persistent pruritic and infiltrated skin reactions after 
vaccinations have been reported in the literature since 
the 1960s (3–6). Later studies have shown an association 
between persistent skin reactions after vaccinations and 
contact allergy to aluminium (7–9). Originally, these 
adverse effects have been considered rare and were 
primarily described in case studies. However, in 2003, 
a Swedish study showed a 0.8% incidence of persistent 
pruritic nodules (645 cases of 76,000 vaccinated child-
ren) related to aluminium-adsorbed childhood vaccines 
produced by Statens Serum Institut (SSI) in Denmark, 
and contact allergy to aluminium was demonstrated in 
77% of the tested patients (10). This is consistent with 
a recent Swedish prospective cohort study reporting an 
incidence of 0.83% of “itching vaccination granulomas” 
(7). Several of the vaccines available in Denmark are 
adsorbed to aluminium, including vaccines in the Danish 
vaccination programme for children (Table SI1). The 
incidence of persistent skin reactions after vaccination 
in Denmark is unknown.
The aim of this retrospective study of patients with 
persistent skin reactions after vaccination in Denmark 
was to investigate the occurrence, clinical presentation, 
diagnostic work-up, course and consequences with 
regard to future vaccinations. 
METHODS
Ethics
Permission to process personal data was obtained from the 
Danish Data Protection Agency (jr. no. 2014-41-2979). Per-
mission from an ethics committee was not needed for this 
observational study.
Participants/questionnaires
Patients were identified through the department’s diagnosis 
code system (T88.1B vaccination granuloma) and a contact 
allergy database (The Allergen Bank), collecting patch-test data 
from approximately 70 dermatologists in private practice and 4 
dermatology departments in Denmark. The patients included in 
the study were tested for delayed hypersensitivity to aluminium, 
by patch-testing with 2% aluminium chloride hexahydrate in 
petrolatum from January 2003 to October 2013. 
To differentiate reactions caused by aluminium in childhood 
vaccines and those caused by other sources of aluminium, only 
children aged 10 years or younger at the time of testing were 
included. A total of 118 patients were tested for aluminium hy-
persensitivity during the 10-year period; 73 patients older than 
10 years (median age 45 years) were excluded (Fig. 1). Data 
were collected from the medical records, and questionnaires 
were sent to the parents of the children in order to collect data 
on clinical manifestations, duration, treatment, consequences 
on the childhood vaccination programme and reporting of the 
adverse effect. 
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RESULTS
A total of 47 children with persistent skin reactions 
after vaccination were identified, comprising 23 girls 
and 24 boys with a mean age of 32 months (age range 
3 months–6.3 years). The majority of children had been 
tested during the last 2 years. Thirty-nine of 42 children 
who were patch-tested had positive reactions to 2% 
aluminium chloride hexahydrate in petrolatum. One 
patient with a negative test had a positive reaction to an 
empty Finn Chamber and was also considered positive, 
giving a total of 40 children with positive tests. Five 
children were diagnosed clinically based on a typical 
history and presentation. In 74% of the children (28 
of 38 for whom data was available), the reaction was 
most likely related to the third dose of the diphtheria, 
tetanus, acellular pertussis, inactivated polio vaccine/
Haemophilus influenzae b conjugate (DTaP-IPV/ Hib) 
vaccine given at 12 months of age (Table I). 
All but 2 patients had itching as their main symptom, 
and two-thirds had a deep nodular infiltrate, also refer-
red to as a granuloma (Table I and Fig. 2). Seventy-one 
percent of the children had moderate discomfort with 
episodic itching, and 21% of the children had severe 
symptoms with intense itching, sometimes causing in-
terrupted sleep. The majority of children were treated 
with topical corticosteroids, sometimes under occlu-
sion. The efficacy of this treatment was described by 
the parents as moderate. 
Three children experienced aggravation of symptoms 
during systemic infections, and 4 reacted anamnesti-
cally to aluminium-containing products (raisins, bread 
mix, sunscreens and aluminium containers), although 
these reactions were not further specified. 
At the time of the query, 66% of the children had 
received all the planned vaccinations, whilst 34% of 
the parents had chosen to postpone or omit further 
vaccination of their child. 
The families received the questionnaires at a median 
of 1.6 years (range 6 months to 9.5 years) after contact 
with a dermatologist. Eighty-four percent of the children 
(32 of 38 for whom data was available) had ongoing 
symptoms at the time of query, despite the fact that 74% 
(28 of 38 for whom data was available) had been treated 
with potent topical corticosteroids. Five children had 
been through a complex diagnostic process involving de-
partments of paediatrics, orthopaedic and plastic surgery, 
including different radiological imaging techniques and 
histopathological examinations of skin specimens, before 
the condition was recognized. In 2 patients malignancy 
was suspected, and one child had the nodule surgically 
removed under general anaesthesia (Fig. 2C). In another, 
the nodule was removed due to the parents’ concern and 
lack of a precise diagnosis. Two patients had skin biopsies 
Table I. Clinical data regarding vaccination granulomas and 
aluminium hypersensitivity after childhood vaccination collected 
from 47 medical records and 39 returned parental questionnairesa 
Suspected vaccine associated with the itching nodules and aluminium 
hypersensitivity
1st dose DTaP-IPV/Hib + PCV 3/38b
2nd dose DTaP-IPV/Hib + PCV 5/38
3rd dose DTaP-IPV/Hib + PCV 21/38
3rd dose DTaP-IPV/Hib + PCV/1st dose measles, mumps rubella 7/38
DTaP-IPV Booster 1/38
Bacillus Calmette-Guérin 1/38
Most common manifestations
Itching 45/47
Nodules/granulomas 32/47
Excoriations 17/47
Eczema 16/47
Hyperpigmentation 15/47
Hypertrichosis 11/47
Infiltration 9/47
Induration 7/47
Superficial wounds 6/47
Intensity of symptoms
Mild (minor symptoms) 3/42
Moderate (episodic itching and irritation) 30/42
Severe (intense itching and sometimes interruption of sleep) 9/42
Duration of symptoms at time of testing
0–6 months 10/43
> 6–12 months 20/43
> 12–18 months 6/43
> 18–24 months 4/43
> 2 years 3/43
Treatment
Topical corticosteroids 36/47
Topical corticosteroids under occlusion 17/47
Occlusion only 1/47
Antihistamines 2/47
Antipruritic cream 3/47
Tacrolimus/pimecrolimus 2/47
Antibiotics 1/47
Excision 2/47
Homeopathic treatment 1/47
No treatment 7/47
Efficacy of treatment
Modest effect 9/29
Partial effect 12/29
Full effect 2/29
No effect 6/29
aDenominator represents number of answers. bOne patient had reactions 
after both 1st and 3rd doses.
DTaP-IPV/Hib: diphteria, tetanus, acellular pertussis, inactivated polio vaccine/
Haemophilus influenzae b conjugate; PCV: pneumococcal conjugate vaccine.
Fig. 1. Included and excluded patients.
The Allergen Bank
Patch test with aluminium chloride hexahydrate 2% in pet.
January 2003–October 2003
118
Positive: 42  Negative: 73  Incomplete data: 3
≤ 10 years of age at time of testing
42
Positive: 39  Negative: 3*
*1 tested positive with empty Finn Chamber
>10 years of age at time of testing
73
Positive: 3  Negative: 70
Patients identified
through the
diagnose code system
at Odense University
Hospital (T88.1b
Vaccination granuloma)
5
Patient records reviewed
47
EXCLUDED
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from their skin lesions and 2 patients had the nodules 
surgically removed. One skin biopsy showed fibrosis 
and the other 3 biopsies showed chronic inflammation. 
Twenty-eight of these adverse reactions to childhood 
vaccines (60%) were reported to the Danish Health and 
Medicines Authority (DHMA) by physicians or parents, 
and 7 of these reactions were also reported to the Danish 
Patient Compensation Association (PCA).
DISCUSSION
The majority of children were seen and tested in 2012 and 
2013, illustrating an apparent increase in the number of 
children referred with persistent skin reactions and alu-
minium hypersensitivity in the last decade. In everyday 
language, we refer to and encode these skin reactions 
as vaccination granulomas, although this is in fact a 
misnomer, as granuloma should be a histopathological 
description. There is also an increased number of reported 
cases to DHMA and PCA (personal correspondence by 
Peter Jakobsen, the Danish Patient Compensation As-
sociation and Mai Frederiksen Raun, the Danish Health 
and Medicines Authority). This is likely to be a result of 
an increased awareness among healthcare professionals 
and the general public, rather than an actual increase 
in incidence. In Denmark aluminium hydroxide is the 
most frequently used adjuvant, and vaccines without 
aluminium are not available at present. SSI previously 
produced a diphtheria-tetanus (DT)-vaccine without 
aluminium (11, 12), but it was withdrawn from the 
market due to the lack of randomized controlled studies 
confirming efficacy and safety. As vaccines are given 
to healthy children on a large scale, the acceptable rate 
of adverse effects is relatively lower than that for other 
pharmaceuticals. Although the overall rate of adverse 
effects to vaccines is low (13), there is a growing scepti-
cism among the general public regarding vaccine safety. 
It has been suggested that the risk of persistent skin 
reactions at the injection sites are higher following 
subcutaneous injections compared with intramuscular 
injections (14), although the importance of the injection 
technique may be overrated (7). Intramuscular injection 
has been the standard recommendation for aluminium-
containing vaccines in Denmark since 1999 (15). We 
know, however, that the administration of vaccines to 
children can be challenging, and even with an intramus-
cular injection, it can be difficult to avoid depositing 
some of the vaccine content subcutaneously.
Forty-seven cases of suspected “vaccination granulo-
mas” and aluminium allergy were reported to the DHMA 
in 2013 (Fig. 3). Supposing that the incidence of 0.83% 
is applicable for the Danish population vaccinated with 
the aluminium-adsorbed childhood vaccines produced 
by SSI, there would be approximately 450 cases of “vac-
cination granulomas” or persistent skin reactions every 
year (0.83% × 55,873 (the Danish birth cohort in 2013)). 
We know that not all side-effects are reported by phy-
sicians or patients, but assume that these reactions may 
also be overlooked by the families of the children and 
Fig. 2. Clinical signs of persistent skin reactions 
and aluminium hypersensitivity. (A) Excoriations, 
hyperpigmentation, hypertrichosis and eczema on the 
lateral thigh. (B) Patch-test showing positive reaction 
(+++) on the 4th day to an empty Finn Chamber (left) 
and to aluminium chloride hexahydrate 2% (right). C. 
Two scars on the left thigh of a 3-year-old child after 
surgical removal of 3 itching nodules.
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Fig. 3. Number of passively reported cases of persistent skin reactions and/
or persistent skin reactions and aluminium allergy.
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healthcare personnel. Five patients from our own depart-
ment were diagnosed with persistent skin reactions after 
vaccination, based on clinical features. This may also 
be the case in private practices, where diagnosis codes 
are not used. Four children were primarily referred to 
departments of paediatrics and, for 2 of these patients, 
the nodular skin lesions were removed surgically.
Clinical features and time course
The most prevalent symptom in this study was long-
lasting, pruritic nodules at the injection sites, and this 
has been similarly documented previously (6, 7, 16–19). 
Excoriations, eczema, hyperpigmentation, hypertrichosis 
and infiltration were other frequently observed symp-
toms. According to the literature, the symptoms vary 
over time, with a more intense primary phase and a less 
eventful healing phase (18). Lidholm et al. and Bergfors 
& Trollfors described a flare of symptoms during inter-
current infections (7, 18), as was the case for 3 patients 
in the current study. 
For the majority of patients, the symptoms occurred 
after the third dose of DTaP-IPV/Hib. A similar obser-
vation was made in 3 other studies (7, 10, 18). This 
suggests a correlation between the number of injections 
with aluminium-adsorbed vaccines and the onset of 
symptoms. Only one of our patients had a reaction to the 
DTaP-IPV booster vaccine administered at the age of 5 
years, which is also in accordance with results from other 
studies (10, 16, 18). Young age seems, therefore, to be a 
risk factor for developing persistent skin reactions and 
aluminium hypersensitivity (20, 21). Another possible 
explanation could be the accumulated aluminium load 
in the 1-year-old child, for whom up to 6 aluminium-
adsorbed vaccines are administered during the first year 
of life. Typically, there is a lag phase between vaccination 
and manifestation of symptoms that may complicate the 
diagnostic process. Based on the duration of symptoms 
and the assumed triggering vaccine, as reported by the 
parents in this investigation, there was a great variation in 
the latency period, ranging from 0 to 18 months. Lidholm 
et al. (7) reported a median latency of 2.5 months (range 
2 weeks to 13 months).
Contact allergy and allergic contact dermatitis to 
aluminium
A total of 93% (39/42) of our tested patients had posi-
tive patch tests to 2% aluminium chloride hexahydrate 
in petrolatum, and one patient reacted to an empty Finn 
Chamber. Bergfors and colleagues reported a preva-
lence of positive patch-test reactions of 77–95% among 
children with persistent skin reactions (7, 10, 18).
Treatment response, prognosis and consequences 
The treatment of pruritic vaccination granulomas is 
symptomatic, with the intention being to break the itch-
scratch cycle. Most of the children in our study were 
treated with topical steroids of potency groups I–IV, 
and sometimes also with occlusion. The efficacy of the 
treatment was often judged by the parents to be unsa-
tisfactory, and a total of 32 of 38 patients in this study 
had ongoing nuisance, lasting a median of 1.6 years 
(range 6 months to 9.5 years) at the time of this study.
The parents described allergic reactions to aluminium-
containing products in 4 children; however, these reactions 
were not further specified or confirmed. Bergfors & Troll-
fors (18) reported 11 cases of allergic contact dermatitis 
reported by the parents following contact with aluminium 
containing deodorants, cosmetics, sunscreens and buttons, 
but the reactions were not objectively confirmed. 
The long-term prognosis of aluminium hypersensi-
tivity has been investigated in a few studies. Kaaber et 
al. (19) retested 4 patients previously diagnosed with 
aluminium hypersensitivity and vaccination granulomas. 
Two of them no longer had positive patch-tests and they 
had no symptoms related to the formerly pruritic nodules. 
Lidholm et al. (17) retested 241 children with long-lasting 
itchy subcutaneous nodules previously diagnosed with 
aluminium allergy. After a follow-up of 5 years or longer, 
186 patients had negative patch-tests. A negative patch-
test correlated significantly with the disappearance of 
clinical symptoms, increasing age, time elapsed since 
first vaccination and test severity of the first positive 
patch-test. Only 3 of 73 tested patients >10 years of age, 
registered in the Allergen bank, had positive patch tests. 
This supports the hypothesis that aluminium allergy in 
relation to childhood vaccinations is temporary and is not 
necessarily maintained in adulthood. The questionnaires 
in the current study revealed that one-third of the parents 
had decided to omit or postpone further vaccination 
of their child. However, only one of the re-vaccinated 
children developed renewed symptoms in the current 
study. Another study showed that only 2 out of 25 re-
vaccinated children developed new pruritic skin lesions, 
which were less severe than earlier reactions (17). Based 
on these observations, it seems safe to be re-vaccinated 
with aluminium-adsorbed vaccines despite previous vac-
cination granuloma and aluminium allergy. 
Study limitations
The results of this study are based on retrospective data 
from medical records and questionnaires sent to the pa-
rents of a selected group of children and may, therefore, 
have limitations due to recall bias and selection of patients. 
The patient records were inadequate with regard to some 
of the questions, e.g. vaccination history and status as well 
as specified reactions to aluminium-containing products. 
There may also be some variation in the interpretation of 
information from the medical records. Follow-up data are 
limited, as most patients were followed for a short period 
of time, although data from questionnaires to the parents 
gave some further information on the course. 
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Conclusion
Awareness of vaccination reactions and persistent skin 
reactions is increasing, and the condition seems to be 
more common than previously assumed; however, it 
may still be overlooked. Persistent skin reactions and 
aluminium hypersensitivity are closely related and can 
be a long-lasting nuisance. We advise treatment with 
potent topical corticosteroids to break the itch-scratch 
cycle. The condition may cause unnecessary anxiety 
for the children and their families, who may postpone 
or opt out of further vaccination. This was the case for 
approximately one-third of the patients in the current 
study. Healthcare personnel, including paediatricians 
and surgeons, should recognize this very characteristic 
condition with long-lasting pruritic nodular infiltrates at 
former injection sites of aluminium-containing vaccines 
in order to avoid unnecessary imaging or surgery. We 
find it valuable to patch-test these children to support 
the significance of aluminium allergy. Parents should be 
encouraged to allow their children to follow the vaccina-
tion programme as scheduled, and physicians should ad-
minister aluminium-containing vaccines intramuscularly.
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